Tech Company Financing Transactions
Novigenix Funding Round
On 12/2/2022, Novigenix raised $20 million in Series B funding from private investors.
Transaction Overview
Company Name
Announced On
12/2/2022
Transaction Type
Venture Equity
Amount
$20,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to fast track the clinical validation of its second generation NGS-based liquid biopsy CRC screening assay, and development of new immunotherapy patient stratification assays. The immuno-transcriptomic cancer-specific profiles obtained from blood draws are combined with multi-modal information such as patient clinical data to predict response to therapy at baseline, and treatment monitoring following therapy.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Route de la Corniche 3 Phenyl Building
Epalinges, CH-1066
CH
Epalinges, CH-1066
CH
Phone
Website
Email Address
Overview
Novigenix biotechnologies generate insights from the response of the immune system to detect disease as early as possible and to provide precision medicine solutions for optimizing the patient's therapeutic journey. We are pioneering the field of Immuno-transcriptomics with passion to improve treatment and health outcomes.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Brian Hashemi
Chief Financial Officer
Christian Jauch
Chief Technical Officer
Sahar Hosseinian
Browse more venture capital transactions:
Prev: 12/2/2022: Le Collectionist venture capital transaction
Next: 12/2/2022: BeeHero venture capital transaction
Share this article
About Our VC Transactions Data
Our team works diligently to record all VC transactions involving tech companies. VC transactions reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs